For example, increase of IL-10+ Bregs isolated from melanoma patients pre-treatment, positively correlated with a lack of response to anti-CTLA-4 treatment, indicating the potential to utilize IL-10+ Bregs as a biomarker for treatment response [143]. Here, IL10 is linked to melanoma.